Antidyslipidemia Pharmacotherapy in Chronic Kidney Disease: A Systematic Review and Bayesian Network Meta-Analysis

Background and Aims: The benefits and safety of antidyslipidemia pharmacotherapy in patients with chronic kidney disease were not well defined so the latest evidence was summarized by this work. Methods: This systematic review and Bayesian network meta-analysis (NMA) included searches of PubMed, Emb...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Guangzhi, Wang, Xiangpeng, Li, Yiming, Chen, Xuefeng, Huang, Ke, Bai, Lin, Ye, Yuyang, Peng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862001/
https://www.ncbi.nlm.nih.gov/pubmed/36678635
http://dx.doi.org/10.3390/pharmaceutics15010006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862001/
https://www.ncbi.nlm.nih.gov/pubmed/36678635
http://dx.doi.org/10.3390/pharmaceutics15010006

Ejemplares similares